التفاصيل البيبلوغرافية
| العنوان: |
Imatinib mesylate-induced acute hepatotoxicity. |
| المؤلفون: |
Frikha, Imen, Fakhfakh, Yousra, Sahnoun, Rim, Chtourou, Lassaad, Medhaffar, Moez, Elloumi, Moez |
| المصدر: |
Journal of Oncology Pharmacy Practice; Dec2023, Vol. 29 Issue 8, p2027-2030, 4p |
| مصطلحات موضوعية: |
HEPATOTOXICOLOGY -- Risk factors, NILOTINIB, CHRONIC myeloid leukemia, HEPATOTOXICOLOGY, IMATINIB, TERMINATION of treatment, PHARMACODYNAMICS |
| مستخلص: |
Introduction: Imatinib is a first-line selective tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia. Although imatinib-induced hepatotoxicity may aggravate the patient's clinical condition and alter the treatment plan, the mechanism of imatinib-induced hepatotoxicity has rarely been investigated. Case report: We report a 51-year-old man, suffering from acute toxic hepatitis after 5 months of imatinib treatment for chronic myeloid leukemia. Management and outcome: The outcome was favorable after discontinuation of treatment with normalization of biological liver function after 12 weeks. The treatment was switched to nilotinib without any incidents. Discussion: Regular liver function test monitoring is recommended during imatinib treatment. In fact of acute hepatic toxicity, treatment with imatinib should be stopped in the case of cytolysis more than five times the upper limit of normal. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Oncology Pharmacy Practice is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder